1.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CABAZ_L_06003, U1111-1123-9025, NCT01649635
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CABAZ_C_05331, 2010-021128-92, U1111-1115-2476, NCT01254279
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC11784, 2010-022064-12, U1111-1117-8356, NCT01308567
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC11785, 2010-022163-35, NCT01308580
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: OGX-011-12, NCT01578655
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BrUOG 243, NCT01365130
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11D.392, 2011-52, NCT01437488
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: F110512012 (UAB 1021), UAB 1021, NCT01438307
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 4P-11-3, NCI-2011-03266, NCT01469338
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARD12166, 2011-003415-31, U1111-1123-3503, NCT01500720
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CABASEM-SOGUG, NCT01518283
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL-ONCO 2011-01, 2011-001938-42, NCT01528163
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16684, NCT01531205
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2011-004178-27, NCT01541007
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-003156-39, NCT01558219
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CABAZ_L_05933, U1111-1119-8381, NCT01576029
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: ISGUOG1101.CTIL, NCT01600339
|
|
19.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ON/2011/3775, 2011-004090-82, NCT01616875
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: BrUOG 246, NCT01650285
|
|
21.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TCD10870, NCT00925743
|
|
22.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: POP6792, U1111-1116-5845, NCT01140607
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 73
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED11576, U1111-1115-4154, NCT01324583
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11-0646(0001)(01), 183133-96-2, NCT01379339
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11D.243, 2011-32, NCT01420250
|
Mobile | Español
